LEXINGTON, Ky., Oct. 12 /PRNewswire/ -- Intranasal Therapeutics, Inc. (ITI) today announced that the U.S. Patent Office has approved a patent for a multiple unit dose delivery device to which ITI holds exclusive worldwide licensing rights.
The programmable delivery system, the product of a research relationship between ITI and the University of Kentucky, is suited for the nasal delivery of narcotics and controlled substances and for ensuring patient compliance. The device can deliver up to 12 individually packaged doses of medication, and it features an electronic lockout system to ensure that a drug is administered no more frequently than the prescription permits. In addition, since doses are packaged individually, dosing accuracy and precision is higher compared with multidose pumps.
“This programmable multiple dose system provides an ideal alternative for controlled drug delivery, which currently is available only as patient- controlled intravenous delivery,” said John C. Carlisle, President and Chief Executive Officer of ITI. “Our successful relationship with the University of Kentucky in developing this device underscores our ability and determination to develop truly differentiated products that provide benefits to patients, their caregivers and health care professionals.”
Patent No. 6,948,492 for the programmable multi-dose intranasal drug delivery device was issued September 27, 2005 to the University of Kentucky Research Foundation in Lexington. The product’s inventors are Daniel Wermeling, Pharm.D., a faculty member of the UK College of Pharmacy who also is ITI’s Chief Scientific Officer, as well as members of the UK College of Engineering. Under an agreement with UK, ITI holds exclusive rights to market the multiple dose delivery device worldwide.
In addition to the delivery device, all of ITI’s nasal spray products are licensed from UK. Since its inception, ITI has worked closely with UK’s College of Pharmacy to develop new nasal products. The College is one of the leading pharmacy schools in the United States and a pioneer in the field of nasal drug delivery research.
Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative nasally delivered pharmaceutical products, with a particular focus on drugs to treat pain and central nervous system disorders for which there is proven, unsatisfied consumer need. The Company currently has four products in its clinical development pipeline, with several others in formulation or preclinical development. ITI’s goal is to become a leader in the field of intranasal pharmaceuticals by applying formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals.
Contact John C. Carlisle President and CEO Intranasal Therapeutics, Inc. Tel.: 859-252-5080 Ext. 226 Fax: 859-252-7280 jcarlisle@intranasal.com
Intranasal Therapeutics, Inc.
CONTACT: John C. Carlisle, President and CEO of Intranasal Therapeutics,Inc., +1-859-252-5080, Ext. 226, or fax, +1-859-252-7280, orjcarlisle@intranasal.com
Web site: http://www.intranasal.com/